Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: A historical perspective

Biochemical and Biophysical Research Communications

Volumn 294, Issue 1, 2002, Pages 1-4

  Deacon, Carolyn F ^a   Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HORMONE; INCRETIN; INSULIN; ISOLEUCINE THIAZOLIDIDE; METFORMIN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALINE PYRROLIDIDE;

DIABETES CONTROL; DRUG ACTIVITY; DRUG DEGRADATION; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ENZYME LOCALIZATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE METABOLISM; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; UREMIA;

EID: 0036290037     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)00359-5     Document Type: Article

References (48)

1. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1
2. Hamster preproglucagon contains the sequence of glucagon and two related peptides
3. Proglucagon 78-107, a potent insulinotropic hormone from lower small-intestine
4. Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas
5. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut
6. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential
7. The glucagon-like peptides
8. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus
9. Insulinotropic action of glucagonlike peptide-I (7-37) in diabetic and nondiabetic subjects
10. Normalization of fasting hyperglycemia by exogenous-1 (7-36 amide) in type 2 GLP diabetic patients
11. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide-1 (7-36) amide in patients with NIDDM
12. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
13. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
14. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients
15. Glucagon like peptide 1 (GLP 1): A trial of treatment in noninsulin dependent diabetes
16. Effect 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: Of a parallel-group study
17. Analysis of the degradation of insulinotropin [GLP-1 (7-37)] in human plasma and production of degradation resistant analogs
18. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum
19. Glucagon-like peptide-1 (GLP-1): Metabolism by human plasma in vitro
20. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo
21. Degradation of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide
22. 2-terminus in type II diabetic patients and in healthy subjects
23. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
24. All products of proglucagon are elevated in plasma from uremic patients
25. Renal catabolism of truncated glucagon-like peptide-1
26. Glucagon-like peptide-1 undergoes differential tissue-specific metabolism in the anesthetized pig
27. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs
28. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
29. Is GLP-1 (9-36) amide an endogenous antagonist at GLP-1 receptors?
30. Glucagon-like peptide-1 (9-36) amide is a major metabolite of glucagon-like peptide-1 (7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
31. Glucagon-like peptide-1 (7-36) amide is transformed to glucagon-like peptide-1 (9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
32. Investigation of glucose-dependent insu-linotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach
33. Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes
34. Dipeptidyl peptidase IV inhibition influences GLP-1 metabolism in vivo
35. Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance
36. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs
37. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isuleucine thiazolidide
38. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide
39. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
40. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
41. Chronic administration of valine pyrrolidide, a selective inhibitor of dipeptidyl peptidase IV, improves glucose tolerance without affecting food intake in Zucker Obese rats
42. Long-term DP IV (P32/98) treatment causes sustained improvements in glucose tolerance, insulin sensitivity, and hyper-insulinemia in falfa Zucker rats
43. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia and β-cell glucose responsiveness in VDF (falfa) Zucker rats
44. Single dose treatment of diabetic patients by the DP IV inhibitor P32/98
45. Treatment with a DPP-IV inhibitor, NVP-DPP728, increases prandial intact GLP-1 levels and reduces glucose exposure in humans
46. Inhibition of DPPIV by NVP DPP728 improves metabolic control over a 4 week period in type 2 diabetes
47. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects
48. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes